Cochlear and NXP Semiconductors sign design and manufacturing agreement

NewsGuard 100/100 Score

Cochlear Limited, Australian based world leader in Implantable Hearing Solutions, and NXP Semiconductors announced today that they have signed an agreement for the design and manufacturing of IC devices for Cochlear’s future generation Implantable Hearing devices.

The agreement includes the definition, development and supply of ultra low power speech processor and wireless communication ICs to be used in Cochlear’s next generation products.

“NXP and Cochlear teams have been working together successfully for several years and our complementary strengths have been key to the development of our market leading implantable hearing solutions,” says Jan Janssen, Senior Vice President, Design & Development at Cochlear. This new agreement extends the partnership into the development and manufacturing of our wireless communication technology even further which is a key component of our future technology developments.

“We are proud to contribute our Ultra Low Power Magnetic Induction Wireless and CoolFlux™ DSP technology to enable Cochlear’s industry leading Hearing Implant solutions,” says Rene Penning de Vries, NXP CTO. “This long-term partnership with Cochlear is another example of NXP’s strategy to achieve leadership in High Performance Mixed Signal application domains. It also illustrates NXP’s engagement in the medical domain, where we target new applications such as wireless (implanted) sensors, medical body area networks and personal healthcare devices.”

Comments

  1. Michael Langhout Michael Langhout United States says:

    This development will hopefully favorably impact size of device, as well as cost.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Supply chain assessment and management, optimizing pharmaceutical supply chains